IGF1R and glioblastoma: The IGV-001 (Figure 1) is a type of cellular immunotherapy that requires the excision of the patient’s primary glioblastoma, followed by ex-vivo treatment with an anti-sense oligodeoxynucleotide against the insulin-like growth factor 1 receptor (IGF-1R) followed by irradiation (NCT04485949) (3, 4).